nanomedicine-2017-keynote

Page 22

Notes:

Biol Med Case Rep 2017 | Volume 1 Issue 2

allied

academies

November 06-07, 2017 | New Orleans, USA

Nanomedicine & Healthcare

Global Meet on

argeteddeliveryof drug incorporatednanoparticles, through

conjugation of tumor-specific cell surface markers, such as

tumor-specific antibodies or ligands can not only enhance the

efficacy of the anticancer drug but also reduce the unwanted

toxicity of the drug. Additionally, multifunctional characteristics

of the nano-carrier system would allow for simultaneous

imaging of tumor mass, targeted drug delivery and monitoring.

A summary of recent progress in nanotechnology, as it relates

specifically to nanoparticles and anticancer drug delivery

will be reviewed. Nano nutraceuticals using combination of

various natural products provide a great potential in cancer

management. Additionally, various nanomedicine approaches

for the detection and treatment of various types of clots

organ specific delivery, vascular targeting, improved PK/PD,

and vaccine will be briefly discussed. Highlight the role of

nanobiotechnology and other enabling technologies in the

followings: Targeted drug delivery; Improved PK and PD; Early

detection (imaging); Targeted delivery of chemotherapy for

optimal efficacy and safety; Nano synthesis and assembly of

various platforms for targeted delivery and nanobiotechnology in

shortening the time and risk of drug discovery and development.

Speaker Biography

Shaker A Mousa is currently an endowed tenure Professor and Executive Vice President

and Chairman of the Pharmaceutical Research Institute and Vice Provost for Research

at ACPHS. Prior to his academic career, he has held a Senior Scientist and Fellow at The

DuPont Pharmaceutical Company for 17 years, where he contributed to the discovery

and development of several FDA approved and globally marketed diagnostics and

therapeutics. He holds over 350 US and International Patents discovering novel anti-

angiogenesis strategies, antithrombotic, anti-integrin, anti-cancer, and non-invasive

diagnostic imaging approaches employing various nanotechnology platforms. He has

published more than 1,000 journal articles, book chapters, patents, and books as

Editor and author. He is a Member of several NIH study sections, Editor-In-Chief, and

on the Editorial Board of several high impact journals. His research has focused on

diagnostics and therapeutics of angiogenesis-related disorders, thrombosis, vascular

and cardiovascular diseases.

Shaker A Mousa

Albany College of Pharmacy and Health Science, USA

Advanced drug delivery: Nano-targeted delivery for therapeutic and imaging